Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

Volume 14 Issue 7, July 2008

Cells from Zmpste24-/- progeroid mice and individuals with Hutchinson-Gilford progeria show nuclear abnormalities that are linked to aging-associated alterations. In this issue, Varela et al. (p 767) show that treatment with statins and aminobisphosphonates improves these aging-like phenotypes and extends lifespan in Zmpste24-null mice. The cover, courtesy of Carlos Lpez-Otn and his colleagues, shows a composition of teeth and cell nuclei from this animal model.

Editorial

  • Some analysts believe that the economic hegemony of the US is on its last legs, but the same does not seem to be true of its scientific supremacy.

    Editorial

    Advertisement

Top of page ⤴

News

Top of page ⤴

Book Review

Top of page ⤴

News & Views

  • The most effective drug to treat acute ischemic stroke, tissue plasminogen activator (tPA), must be applied within three hours after symptom onset because of the risk of hemorrhage and other complications such as neurotoxicity. The anticancer drug imatinib (Gleevec) may help overcome these limitations by counteracting the ability of tPA to increase the permeability of the blood-brain barrier (pages 731–737).

    • Peter Rieckmann
    News & Views
  • Two commonly prescribed drugs, statins and aminobisphosphonates, may be helpful in combating the rare aging disorder, Hutchinson-Gilford progeria syndrome (pages 767–772).

    • Eran Meshorer
    • Yosef Gruenbaum
    News & Views
  • Gallstone disease occurs more frequently in subjects with the metabolic syndrome and type 2 diabetes. Findings in a mouse model suggest that the forkhead transcription factor FoxO1 lies behind this association (pages 778–782).

    • Folkert Kuipers
    • Albert K Groen
    News & Views
Top of page ⤴

Community Corner

Top of page ⤴

Research Highlights

Top of page ⤴

Between Bedside and Bench

  • Endocannabinoids are versatile molecules, regulating a variety of functions in the body. Daniele Piomelli explores how recent clinical trials testing rimonabant, an inhibitor of endocannabinoid signaling, for weight loss emerged from studies of individuals with schizophrenia; such trials have spurred basic research into how endocannabinoids affect both energy use and mood. Beat Lutz and Krisztina Monory examine how rimonabant might prove useful for preventing the development of adult epilepsy in response to fever-induced seizures in infants and young children.

    • Beat Lutz
    • Krisztina Monory
    Between Bedside and Bench
Top of page ⤴

Article

Top of page ⤴

Letter

Top of page ⤴

Technical Report

  • Noninvasively monitoring immune function by positron emission tomography could affect the diagnosis and treatment evaluation of immunological disorders. Progress, however, has been hampered by the lack of probes with distinct biodistribution patterns. Radu et al. exploit the fact that many immune cells utilize a salvage pathway for nucleotide generation during DNA synthesis to develop [18F]FAC (1-(2′-deoxy-2′[18F]fluoroarabinofuranosyl) cytosine), a new probe with increased accumulation in proliferating T cells. Studies in mice show it has advantages over commonly used probes and may be clinically useful.

    • Caius G Radu
    • Chengyi J Shu
    • Owen N Witte
    Technical Report
Top of page ⤴

Erratum

Top of page ⤴

Search

Quick links